Corvus Pharmaceuticals (CRVS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CRVS · Stock Price

USD 14.59+10.16 (+229.35%)

Market Cap: $1.3B

Historical price data

Market Cap: $1.3BPipeline: 10 drugs (2 Phase 3)Patents: 15Founded: 2014HQ: Burlingame, United States

Sector Ranking#167 in Small Molecule Drugs #41 in Oncology (General)

Overview

Corvus Pharmaceuticals is a clinical-stage biotech focused on developing precisely-targeted small molecule therapies for cancer and immune diseases, anchored by its proprietary ITK inhibition platform. Its lead asset, soquelitinib, is a first-in-class oral ITK inhibitor designed to modulate T cell differentiation, with multiple Phase 1/1b trials underway in T cell lymphomas and solid tumors. The company's strategy emphasizes establishing monotherapy proof-of-concept to de-risk development, guided by a leadership team with seminal experience in bringing blockbuster oncology drugs like Rituxan and Imbruvica to market.

OncologyImmunology

Technology Platform

Selective inhibition of Interleukin-2-inducible T cell kinase (ITK), an intracellular tyrosine kinase expressed in T cells and NK cells, designed to modulate T cell differentiation (towards Th1, away from Th2/Th17) and enhance immune responses.

Pipeline

10

10 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
CPI-006 2 mg/kg + SOC + CPI-006 1 mg/kg + SOC + Placebo + SO...	Covid-19	Phase 3
Soquelitinib + Belinostat + Pralatrexate	Peripheral T-Cell Lymphoma, Not Otherwise Specified	Phase 3
Soquelitinib + Placebo	Atopic Dermatitis	Phase 2
Soquelitinib + Placebo	Atopic Dermatitis	Phase 1
Ciforadenant + daratumumab	Multiple Myeloma	Phase 1

Funding History

3

Total raised:$185M

IPO$75MUndisclosedApr 7, 2016

Series B$75MOrbiMedOct 15, 2015

Series A$35MOrbiMedJun 15, 2014

Opportunities

Soquelitinib's dual potential in oncology (T-cell lymphomas, solid tumors) and immunology (asthma, autoimmune diseases) addresses multi-billion dollar markets with high unmet need.

The company's first-mover status in selective ITK inhibition and its leadership's proven drug development track record provide significant competitive advantages for capturing this value.

Risk Factors

The company faces high clinical development risk as its entire value hinges on unproven Phase 1/1b data.

Financial risk is elevated due to pre-revenue status and the need for future capital raises, likely causing dilution.

Commercial competition in target markets, especially immunology, is intense from large, entrenched pharmaceutical companies.

Competitive Landscape

In T-cell lymphomas, soquelitinib competes with niche oncology agents like HDAC and PI3K inhibitors, differentiating via its novel mechanism. In broader immunology/oncology, it would face massive competition from PD-1/L1 inhibitors and targeted cytokine blockers. Its key advantage is being the first selective ITK inhibitor in clinical development, backed by a uniquely experienced team.